INTRODUCTION
Total body fat content, as measured by dual X-ray absorptiometry (DXA), is highly correlated with multiple metabolic risk factors [1] . Intra-abdominal (visceral) adipose tissue (VAT) also influences cardiometabolic risk factors independent of total body fat and is a major risk factor for many of the cardiometabolic complications of obesity [2] [3] [4] [5] [6] . Although various adipose depots can be accurately measured using dedicated imaging techniques, implementation of these modalities remain limited in clinical practice due to high cost, radiation exposure, and prolonged scan time. Multiple surrogate indices of total and visceral adiposity have been developed that do not require advanced imaging, have been validated with metabolic outcomes, and are more readily applied in the clinical setting [7] [8] [9] . Furthermore, the individual parameters used to derive these indices can be applied across a broad spectrum of populations.
Empagliflozin (EMPA) is a potent and selective sodium glucose cotransporter 2 inhibitor [10] . In a Phase III, randomized, if 0.5-0.7, and high if 0.7-0.9 [16] . For all statistical testing, a 2-sided P value\0.05 was considered statistically significant. All statistical analyses were performed using SAS version 9.2 software (SAS Corporation, Cary, NC).
Compliance with Ethics Guidelines
All procedures followed were in accordance with the ethical standards of the responsible 
RESULTS
Baseline characteristics of 118 patients with a baseline DXA (n = 93) or MRI (n = 99) scan are shown in Table 1 . Patients with a baseline scan had a mean age of 55.6 years and were predominantly female and white. Body weight, WC, eTBF, ICO, and VAI were similar between DXA and MRI scanned groups. 
DISCUSSION
In this post hoc analysis using a subset of the 1549 patients with T2D randomized to treatment with EMPA vs. glimepiride in the EMPA-REG H2H SU trial with baseline DXA or MRI, we found that eTBF (using sex-specific equations incorporating weight and WC) was highly representative of total body fat mass by healthy men and women) [17] . It also has a strong association with cardiovascular disease risk and mortality [18] . As a result, the American Heart Association/National Heart, Lung, and
Blood Institute has incorporated WC as a surrogate marker of abdominal/central obesity in their diagnostic definition of the metabolic syndrome [19] . ICO, the index of WC to height, has also been extensively studied and may be superior to WC in predicting multiple cardiovascular risk factors in both sexes and different ethnic groups [20] . Several study limitations merit comment. First, we are unable to report on the association of waist-hip ratio with direct imaging phenotypes as hip circumference was not measured in our study. Second, subgroup analyses by sex and age were not performed due to a limited sample size and the concern that multiple subgroup analyses on a limited patient sample may substantially increase the probability of false-positive findings [22] .
Further research should focus on validating these indices within larger, more diverse populations, including age-and sex-specific analyses given their strong influence on adipose distribution.
CONCLUSIONS
In conclusion, using baseline data from the EMPA-REG H2H SU trial, we found strong correlations between the adipose distribution indices of eTBF (YMCA formula) and total body fat by DXA and between WC and ICO and 
